Skip to main navigation Skip to search Skip to main content

Co-clustering of EphB6 and ephrinB1 in trans restrains cancer cell invasion

  • Lung Yu Liang
  • , Niall D. Geoghegan
  • , Michael Mlodzianoski
  • , Andrew Leis
  • , Lachlan W. Whitehead
  • , Minglyanna G. Surudoi
  • , Samuel N. Young
  • , Peter Janes
  • , Doulin Shepherd
  • , Debnath Ghosal
  • , Kelly L. Rogers
  • , James M. Murphy
  • , Isabelle S. Lucet

Research output: Contribution to journalArticleResearchpeer-review

Abstract

EphB6 is an understudied ephrin receptor tyrosine pseudokinase that is downregulated in multiple types of metastatic cancers. Unlike its kinase-active counterparts which autophosphorylate and transmit signals upon intercellular interaction, little is known about how EphB6 functions in the absence of intrinsic kinase activity. Here, we unveil a molecular mechanism of cell-cell interaction driven by EphB6. We identify ephrinB1 as a cognate ligand of EphB6 and show that in trans interaction of EphB6 with ephrinB1 on neighboring cells leads to the formation of large co-clusters at the plasma membrane. These co-clusters exhibit a decreased propensity towards endocytosis, suggesting a unique characteristic for this type of cell-cell interaction. Using lattice light-sheet microscopy, 3D structured illumination microscopy and cryo-electron tomography techniques, we show that co-clustering of EphB6 and ephrinB1 promotes the formation of double-membrane tubular structures between cells. Importantly, we also demonstrate that these intercellular structures stabilize cell–cell adhesion, leading to a reduction in the invasive behavior of cancer cells. Our findings rationalize a role for EphB6 pseudokinase as a tumor suppressor when interacting with its ligands in trans.

Original languageEnglish
Article number461
Number of pages13
JournalCommunications Biology
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  • ARC Industrial Transformation Training Centre for Cryo-Electron Microscopy of Membrane Proteins for Drug Discovery

    Sexton, P. (Primary Chief Investigator (PCI)), Rouiller, I. (Chief Investigator (CI)), Wootten, D. (Chief Investigator (CI)), van Oijen, A. (Chief Investigator (CI)), Parker, M. W. (Chief Investigator (CI)), Lucet, I. (Partner Investigator (PI)), Griffin, M. D. W. (Chief Investigator (CI)), Adams, D. J. (Chief Investigator (CI)), Czabotar, P. E. (Partner Investigator (PI)), Flocco, M. (Partner Investigator (PI)), Shepherd, R. K. (Partner Investigator (PI)), Ciferri, C. (Partner Investigator (PI)), Williams, P. A. (Partner Investigator (PI)), Brown, D. (Partner Investigator (PI)), Schreuder, H. (Partner Investigator (PI)), Reedtz-Runge, S. (Partner Investigator (PI)), Drinkwater, C. (Partner Investigator (PI)), Howard, B. L. (Partner Investigator (PI)), Betigeri, G. (Partner Investigator (PI)), Pryor, E. (Partner Investigator (PI)), How, J. (Project Manager), Pierce, T. (Project Manager) & How, J. (Project Manager)

    Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom)

    23/03/2123/03/27

    Project: Research

Cite this